Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $77.17

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been assigned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $77.1667.

Several analysts have recently issued reports on CORT shares. Truist Financial set a $50.00 target price on Corcept Therapeutics in a research note on Wednesday, December 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price for the company. in a research report on Wednesday, December 31st. UBS Group assumed coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Finally, Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Short‑interest posts for March 3–4 show zero/NaN values and a 0.0 days‑to‑cover figure — the data in these feeds appears inconsistent and does not indicate a clear increase in bearish positioning. (No article link)
• Neutral Sentiment: Independent analyst/head‑to‑head coverage was published comparing Corcept to peers (background/context piece); such coverage is informational and not an immediate catalyst. Corcept Therapeutics (NASDAQ:CORT) & Madrigal Pharmaceuticals Head-To-Head Analysis
• Negative Sentiment: A broad wave of shareholder‑rights firms (Hagens Berman, Rosen, Pomerantz, Levi & Korsinsky, Frank R. Cruz, Bronstein Gewirtz & Grossman, Glancy Prongay, Schall, et al.) have alerted investors and/or filed a securities class action (Allegheny County Employees’ Retirement System v. Corcept). These notices allege the company ignored FDA warnings and concealed “evidence gaps,” and they encourage filings ahead of the April 21 lead‑plaintiff deadline — increasing litigation risk, potential legal costs, and reputational pressure. Representative notices: Hagens Berman (details on alleged FDA warnings and prior 50% stock drop). Hagens Berman Alerts Corcept Investors Rosen Law Firm notice. Rosen Law Firm Notice Other firm notices include GlobeNewswire/BusinessWire posts from Pomerantz, Schall, Glancy, and others.

Insider Activity

In related news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total value of $817,400.00. Following the sale, the insider directly owned 1,235 shares in the company, valued at approximately $50,474.45. The trade was a 94.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 20.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Pathstone Holdings LLC boosted its stake in Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after purchasing an additional 144 shares during the period. Huntington National Bank boosted its position in shares of Corcept Therapeutics by 54.0% in the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 168 shares during the period. Campbell Newman Asset Management Inc. boosted its position in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock valued at $2,953,000 after acquiring an additional 170 shares during the period. Nisa Investment Advisors LLC grew its stake in Corcept Therapeutics by 1.8% during the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 180 shares in the last quarter. Finally, Clearstead Advisors LLC increased its holdings in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the period. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $35.69 on Monday. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $41.54 and its 200-day moving average price is $64.95. The firm has a market capitalization of $3.80 billion, a P/E ratio of 43.52 and a beta of 0.29. Corcept Therapeutics has a 1-year low of $28.66 and a 1-year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.26 EPS. Equities research analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.